Sight Sciences Inc (SGHT) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Sight Sciences Inc stock $7.38, price $10.59, that is 30.3% below the price, quality 51 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Sight Sciences Inc
SGHT · USExpensive (fair value 30% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $1.29 – $38.38 · fair‑value band $5.53 – $9.22 · the $10.59 price screens above the $7.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Sight Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
Show moreShow less
The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.
The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists.
It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Stock analysis
Sight Sciences Inc (SGHT) currently trades at $10.59, while our estimate is $7.38, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $5.53 (bear) to $9.22 (bull), the price of $10.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sight Sciences Inc reported revenue of $77.4M in FY2025 versus $49.0M in FY2021, a compound +12.1%/yr. Reported net income was −$38.4M in FY2025.
Key figures
Market cap $577M Small · P/S ratio 6.92 · EPS (TTM) $−0.5200 · Net margin −32.1% · Return on equity −50.1% · Return on assets (EBIT) −31.9% (5-year average) · Operating margin −24.6% · Revenue (TTM) $88.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 207% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −30%, SGHT screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $68,808, on Jun 10, 2026. Over the same period, 6 people sold shares worth $1.2M.
- SaleJames RodbergChief Financial Officer6× since Dec 2, 2025: 31,474 shares, avg. $6.46$203,459Oct 2, 2026
- SaleAlison BauerleinChief Operating Officer5× since Jan 5, 2026: 108,589 shares, avg. $6.13$665,828Oct 2, 2026
- SaleBrenton TaylorEVP, Operations & R&D5× since Nov 17, 2025: 23,723 shares, avg. $6.69$158,822Oct 2, 2026
- SalePaul BadawiPresident and CEO, Director, 10% owner5× since Jan 2, 2026: 147,169 shares, avg. $6.50$957,219Oct 1, 2026
- SaleDavid BadawiChief Technology Officer, Director5× since Jan 2, 2026: 37,879 shares, avg. $6.47$245,016Oct 1, 2026
- SaleJeremy B. HaydenChief Legal Officer5× since Nov 25, 2025: 88,822 shares, avg. $6.87$609,900Jul 6, 202610b5-1 plan
- BuyStaffan EncrantzDirector, 10% owner2× since Dec 16, 2025: 28,058 shares, avg. $6.59$184,799Jun 10, 2026
Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
SGHT screens overvalued: fair value 30% below the price. Compare with Abbott Laboratories, →
Compare Sight Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| DexCom, Inc DXCM | $81.61 | $91.66 | +12% | vs SGHT |
| Boston Scientific Corporation BSX | $43.69 | $48.77 | +12% | vs SGHT |
| Stryker Corporation SYK | $310.72 | $340.60 | +10% | vs SGHT |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥184.30 | ¥197.34 | +7% | vs SGHT |
| GE HealthCare Technologies Inc GEHC | $82.96 | $69.92 | −16% | vs SGHT |
| Siemens Healthineers AG SHL | €44.00 | €34.51 | −22% | vs SGHT |
| Edwards Lifesciences Corporation EW | $107.11 | $81.94 | −24% | vs SGHT |
| Medtronic plc MDT | $102.88 | $74.89 | −27% | vs SGHT |
| Abbott Laboratories, ABT | $107.45 | $75.28 | −30% | vs SGHT |
| Koninklijke Philips N.V PHIA | €27.54 | €15.23 | −45% | vs SGHT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sight Sciences Inc (SGHT) overvalued or undervalued?
What is the fair value of SGHT?
What is the quality score of SGHT?
What is the price target for Sight Sciences Inc (SGHT)?
What is the Sight Sciences Inc stock forecast for 2026?
What is the revenue of Sight Sciences Inc (SGHT)?
What is the intrinsic value of Sight Sciences Inc (SGHT)?
Is Sight Sciences Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SGHT?
How much is Sight Sciences Inc worth?
What do the bullish and bearish scenarios say about SGHT?
How solid is the balance sheet of Sight Sciences Inc (SGHT)?
How far is SGHT from its 52-week high?
Which stocks are comparable to Sight Sciences Inc?
Is Sight Sciences Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Sight Sciences Inc (SGHT)?
What should I pay attention to with Sight Sciences Inc right now?
Key figures of Sight Sciences Inc
How large is the market capitalisation of Sight Sciences Inc (SGHT)?
What is the P/S ratio of Sight Sciences Inc (SGHT)?
What are the earnings per share of Sight Sciences Inc (SGHT)?
What is the net margin of Sight Sciences Inc (SGHT)?
What is the return on equity of Sight Sciences Inc (SGHT)?
What is the EBIT return on assets of Sight Sciences Inc (SGHT)?
What is the operating margin of Sight Sciences Inc (SGHT)?
How fast is revenue growing at Sight Sciences Inc (SGHT)?
How much free cash flow does Sight Sciences Inc (SGHT) generate?
How much net cash does Sight Sciences Inc (SGHT) hold?
Watch Sight Sciences Inc in the live analysis
One click puts Sight Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.